IQVIA's Market Feedback Report (MFR) and PharmaTrac's Acquaint report both analyze the Indian Pharmaceutical Market (IPM) for November 2025, revealing consistent growth trends driven by chronic therapies despite minor data discrepancies.
MFR reports MAT sales at ₹246,846 Cr with 8.2% growth, while PharmaTrac shows ₹238,968 Cr at 8.8% YoY and 8.8% 5-year CAGR. Critical analysis highlights strong chronic momentum but questions volume sustainability amid price hikes and new launches.[1][2]
Market Growth Comparison
MetricIQVIA MFR (MAT Nov25) [1]PharmaTrac Acquaint (MAT Nov25) [2]Total IPM Value₹246,846 Cr (8.2% growth)₹238,968 Cr (8.0% YoY, 8.8% CAGR)Monthly Nov25 Sales₹21,679 Cr (8.6% MoM adjusted)₹21,182 Cr (9.1% YoY)Incremental ValueNot specified₹1,759 Cr YoYAcute Growth6.3%5.4% (44% market share)Chronic Growth11.1%13.3% (35% share, led Cardiac/Anti-Diabetic)
Free Membership Required
You must be a Free member to access this content.
